Sellas Life Sciences Group Inc recorded a cumulative net loss of $-32 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 362 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 4046, from total ranking in previous quarter at 4792.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SLS Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-2,497,000	-2,265,923	-2,066,385	-1,995,538	-2,019,923
SLS's Total Ranking	# 4046	# 4792	# 4195	# 4266	# 4300
Seq. Net Income Change	-	-	-	-	-

SLS Company Profile >> Back to SLS Efficiency Comparisons >> Compare SLS Net Income per Employee to its Competitors

SLS Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 363
Healthcare Sector	# 805
Overall Market	# 4046

Net Income per Employee Statistics
High	Average	Low
$ -737,846	$ -2,629,109	$ -6,178,634
(Mar 31 2014)		(Mar 31 2016)

News about Sellas Life Sciences Group Inc Income per employee

The landscape of cancer treatment is evolving with the advent of targeted therapies, which ai...

Emergence of SLS009 and Galinpepimut-S: Targeted Therapeutics in the Fight Against Relapsed and Refractory Acute Myeloid Leukemia and Solid Tumors The landscape of cancer treatment is evolving with the advent of targeted therapies, which aim to improve efficacy while minimizing adverse effects. SELLAS Life Sciences has made significant strides in this arena with its investigational drugs SLS009 and Galinpepimut-S (GPS). This article synthesizes findings from two pivotal studies: the Phase 2 trial of SLS009 in r/r Acute Myeloid Leukemia (AML) and preclinical studies emphasizing the potential of ASXL1 mutations as predictive markers for SLS009 efficacy in solid tumors. In addition, we discuss the recent U.S. FDA designation of GPS for pediatric patients, underscoring the importance of developing treatments tailored to specific populations. Acute Myeloid Leukemia (AML) is a heterogeneous disease characterized by the rapid proliferation of abnormal myeloid precursors, and it poses significant challenges in treatment, particularly for patients who have relapsed or are refractory to existing therapies. This cohort often relies on alternative therapeutic avenues, and targeted agents are particularly promising.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-08T22:17:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.